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creativecommons.org/licenses/by-nc-nd/Abstract Purpose: The primary analysis of the ASPECCT study demonstrated that panitu-
mumab was non-inferior to cetuximab for overall survival (OS) in patients with
chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (mCRC). Here,
we report the final analysis results of ASPECCT.
Patients and methods: Patients with wild-type KRAS exon 2 mCRC who progressed on or
were intolerant to irinotecan- or oxaliplatin-based chemotherapy were randomised to receive
panitumumab 6 mg/kg once every 2 weeks or cetuximab (400 mg/m2) followed by 250 mg/m2
weekly. The primary end-point was OS assessed for non-inferiority. Patients were followed forof Haematology-Oncology, The Queen Elizabeth Hospital, Woodville, SA 5011, Australia. Fax: þ61 8
v.au (T. Price).
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T. Price et al. / European Journal of Cancer 68 (2016) 51e5952survival for 24 months after the last patient was randomised and a final analysis was conduct-
ed. No formal hypothesis testing was done. Post hoc analyses of outcomes by prior bevacizu-
mab exposure, worst-grade skin toxicity (0e1 versus 2e4) and worst-grade hypomagnesaemia
(0 versus 1e4) were conducted.
Results: Nine hundred ninety-nine patients were randomised and received 1 treatment dose
(panitumumab, n Z 499; cetuximab, nZ 500). Median OS was 10.2 months with panitumu-
mab versus 9.9 months with cetuximab (hazard ratioZ 0.94; 95% confidence intervalZ 0.82
e1.07). Median progression-free survival was 4.2 months with panitumumab and 4.4 months
with cetuximab (hazard ratioZ 0.98; 95% confidence interval Z 0.87e1.12). Longer OS was
observed for patients with increased skin toxicity and with hypomagnesaemia in both arms.
Furthermore, OS was longer for patients with prior bevacizumab exposure treated with pani-
tumumab than with cetuximab. The observed safety profiles were consistent with previous
studies.
Conclusion: Consistent with the primary analysis, the final analysis of ASPECCT showed pa-
nitumumab was non-inferior to cetuximab for OS for patients with chemotherapy-refractory,
wild-type KRAS exon 2 mCRC.
Trial registration: ClinicalTrials.gov, NCT01001377.
ª 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
For patients with metastatic colorectal cancer (mCRC),
improvements in survival after irinotecan- or
oxaliplatin-based chemotherapy in combination with
targeted therapies [1e5] likely lead to an increase in
patients eligible for third-line treatment. Panitumumab,
a fully human monoclonal antibody targeting the
epidermal growth factor receptor (EGFR), and cetux-
imab, a chimeric anti-EGFR antibody, have demon-
strated clinical efficacy in patients with chemotherapy-
refractory wild-type KRAS exon 2 mCRC [6e9]. In
the phase 3 CO.17 study, cetuximab monotherapy
improved overall survival (OS) and progression-free
survival (PFS) versus best supportive care (BSC) in
patients with wild-type KRAS exon 2 tumours [10,11].
Similarly, in the phase 3 20020408 study, panitumumab
in combination with BSC improved PFS in patients with
wild-type KRAS exon 2 mCRC, versus BSC alone
[12e14]. A statistically significant OS benefit was not
seen with panitumumab monotherapy in the 20020408
study, potentially because of patient crossover from the
BSC arm (i.e. from BSC to panitumumab plus BSC after
disease progression) [12].
ASPECCT was the first head-to-head, randomised,
phase 3 study to evaluate efficacy and safety of pan-
itumumab versus cetuximab for treatment of
chemotherapy-refractory wild-type KRAS exon 2
mCRC. The primary analysis demonstrated that pan-
itumumab was non-inferior to cetuximab, and the an-
tibodies provided a similar OS benefit to this patient
population (median, 10.4 months versus 10.0 months; Z-
score Z 3.19; P Z 0.0007; hazard ratio [HR] Z 0.97;
95% confidence interval [CI] Z 0.84e1.11) [15]. Safety
profiles were similar between groups [15]. We reportresults of the prespecified final descriptive analysis of
outcomes in the ASPECCT study, which was planned
for 24 months after the final patient was randomised,
and results from ad hoc subgroup analyses by prior
bevacizumab, skin toxicity, and hypomagnesaemia.
2. Patients and methods
2.1. Study design and patients
Detailed information regarding patient inclusion
criteria, study design, and treatment schedules has been
previously reported and is described in the Appendix
[15]. The protocol received institutional/ethical
approval at each site. Patients provided written
informed consent.
2.2. Treatment
Patients received either panitumumab (6 mg/kg) intra-
venously on day 1 of each 14-day cycle or cetuximab at
an initial dose of 400 mg/m2 intravenously followed by
250 mg/m2 intravenously on day 1 of each 7-day cycle.
Patients in the cetuximab arm received treatment
consistent with product labelling in their respective
countries, including premedication with an H1 antago-
nist before infusion; premedication for infusion reaction
was not required for panitumumab. Treatment
continued until disease progression, intolerability or
withdrawal of consent.
2.3. Study end-points
The primary end-point was OS (defined as time from
randomisation to death) assessed for non-inferiority.
Efficacy analysis set (n=499) 
Safety analysis set* (n=496) 
Enrolled (n=1010)
Assigned to panitumumab (n=506)
Discontinued the study (n=497)
Death (n=444)
Consent withdrawn (n=17)
Lost to follow-up (n=21)
Administrative decision (n=15)
Discontinued panitumumab (n=497)
Disease progression (n=426) 
Adverse event (n=31)
Death (n=17)
Consent withdrawn (n=16)
Non-compliance (n=3)
Lost to follow-up (n=1)
Other (n=3)
Continuing panitumumab (n=2)
Efficacy analysis set (n=500) 
Safety analysis set* (n=503) 
Discontinued the study (n=500)
Death (n=454)
Consent withdrawn (n=16)
Lost to follow-up (n=15)
Administrative decision (n=14) 
Ineligible (n=1)
Discontinued cetuximab (n=500)
Disease progression (n=429) 
Adverse event (n=26)
Death (n=15)
Consent withdrawn (n=21)
Non-compliance (n=2)
Ineligible (n=2)
Administrative decision (n=1)
Protocol violation (n=1)
Other (n=3)
Assigned to cetuximab (n=504)
Received panitumumab* (n=499) Received cetuximab* (n=500)
Not treated (n=7) Not treated (n=4)
Fig. 1. Disposition of patients in the study (CONSORT). *Four patients were randomly assigned to the panitumumab arm but received
cetuximab treatment because of a randomisation notification error; one patient was randomly assigned to cetuximab but received pan-
itumumab because of a misunderstanding of the randomisation notification at the treatment site.
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from randomisation to disease progression/death),
objective response rate (ORR) and safety.2.4. Statistical analysis
This non-inferiority study was designed to demonstrate
that panitumumab retained 50% of the OS treatment
effect of cetuximab versus BSC (previously reported; see
Appendix). After the primary analysis, data continued
to be collected for patients remaining on study. All pa-
tients were followed for survival for 24 months after the
last patient was randomised. No formal hypothesis
testing was planned for this analysis; however, descrip-
tive statistics of key efficacy and safety end-points were
updated. The primary analysis set included all patients
who received 1 dose of panitumumab or cetuximab;
patients were analysed according to the treatment to
which they were randomised. The safety analysis set
included all patients who received 1 dose of pan-
itumumab or cetuximab; patients were analysed ac-
cording to treatment received.Post hoc analyses of outcomes by prior bevacizumab
exposure, worst-grade skin toxicity (0e1 versus
2e4) and worst-grade hypomagnesaemia (0 versus 1e4)
were also conducted (Appendix). For hypo-
magnesaemia, additional analyses of outcomes by
worst-grade hypomagnesaemia and magnesium reduc-
tion (20% versus <20%) were performed at week 5.
Stratified Cox proportional hazards models were used to
examine relationships between subgroups, OS and PFS.3. Results
3.1. Patients
Between February 2010 and July 2012, 1010 patients
with wild-type KRAS exon 2 mCRC were randomised.
Of these, 999 patients received 1 dose of study treat-
ment (panitumumab, n Z 499; cetuximab, n Z 500;
Fig. 1). Baseline characteristics were balanced between
arms (Table 1). Post-progression antitumour therapy
was similar between arms (Table A1). Median follow-up
time for all patients was 41.3 weeks.
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3.2.1. Overall survival
At the time of final analysis (September 15, 2014), 446
patients (89%) patients treated with panitumumab and
456 patients (91%) treated with cetuximab had died,
versus 383 (77%) and 392 (78%), respectively, reported
in the primary analysis (February 5, 2013). Median OS
times with panitumumab and cetuximab treatment were
10.2 months and 9.9 months, respectively (HR Z 0.94;
95% CI Z 0.82e1.07; P Z 0.0002; Fig. 2A). The
retention rate was 1.11, indicating that panitumumab
treatment preserved 111% of the cetuximab OS benefit.
The non-inferiority test was positive (Z-score Z 3.58;
P Z 0.0002), consistent with the primary analysis re-
sults. OS was similar between treatment arms across
most patient subgroups (Fig. 2B).
3.2.2. Progression-free survival
At the time of the final analysis, 486 patients (97%)
treated with panitumumab and 490 (98%) patients
treated with cetuximab had had a PFS event. Median
PFS was 4.2 months in the panitumumab arm and
4.4 months in the cetuximab arm (HR Z 0.98; 95%
CI Z 0.87e1.12; Fig. 2C). PFS was similar between
treatment arms for all patient subgroups analysed
(Fig. 2D).Table 1
Baseline demographic and clinical characteristics.
Characteristic Panitumumab
(n Z 499)
Cetuximab
(n Z 500)
Men 315 (63.1) 318 (63.6)
White 266 (53.3) 258 (51.6)
Median (range) age, y 61.0 (19e86) 60.5 (20e89)
Region
North America/Western
Europe/Australia
154 (30.9) 156 (31.2)
Rest of world 345 (69.1) 344 (68.8)
ECOG PS
0 154 (30.9) 163 (32.6)
1 303 (60.7) 297 (59.4)
2 42 (8.4) 40 (8.0)
Prior radiotherapy 131 (26.3) 128 (25.6)
Prior bevacizumab 126 (25.3) 132 (26.4)
Refractory to oxaliplatin or
irinotecana
495 (99.2) 496 (99.2)
Location of primary tumour
Colon 292 (58.5) 326 (65.2)
Rectum 207 (41.5) 174 (34.8)
Sites of metastatic disease
Liver only 52 (10.4) 50 (10.0)
Other sites  liver 447 (89.6) 450 (90.0)
Data are expressed as n (%) unless otherwise noted.
ECOG PS Z Eastern Cooperative Oncology Group Performance
Status.
a Failure of a prior regimen containing irinotecan for metastatic
disease and a prior regimen containing oxaliplatin for metastatic dis-
ease was an eligibility requirement for enrolment in ASPECCT. Oxa-
liplatin and irinotecan may have been administered sequentially or in
combination.3.2.3. Objective response rate
ORR (95% CI) was 22.0% (18.4%e26.0%) in the pan-
itumumab arm and 19.8% (16.3%e23.6%) in the
cetuximab arm (odds ratio Z 1.15; 95%
CI Z 0.83e1.58; Table A2). Two patients (0.4%) in the
panitumumab arm and zero patients (0%) in the cetux-
imab arm had a complete response.
3.3. Safety
The safety analysis included 496 patients in the pan-
itumumab arm and 503 patients in the cetuximab arm.
The overall incidence of treatment-emergent AEs was
similar between patients treated with panitumumab and
cetuximab for AEs of any grade (98%, 98%), serious
AEs (30%, 34%), grade 3 AEs (37%, 32%) and grade 4
AEs (8%, 5%). The incidence of fatal AEs was the same
as in the primary analysis: 29 patients (6%) in the pan-
itumumab arm and 50 patients (10%) in the cetuximab
arm.
Adverse events that occurred in 10% of patients in
either treatment arm are summarised in Table 2. The
incidence of grade 3/4 hypomagnesaemia was greater
among patients who received panitumumab (7%) versus
cetuximab (3%). Six patients (1.2%) in the panitumumab
arm and two (0.4%) in the cetuximab arm discontinued
treatment because of hypomagnesaemia. Furthermore,
25 patients (5%) in the panitumumab arm and 14 pa-
tients (3%) in the cetuximab arm underwent dose mod-
ifications for hypomagnesaemia. Grade 3/4 infusion
reactions occurred in 1 (0.2%) in the panitumumab arm
and 9 (1.8%) patients in the cetuximab arm.
3.4. Outcomes by prior bevacizumab therapy
In total, 126 patients (25%) in the panitumumab arm
and 132 patients (26%) in the cetuximab arm received
prior bevacizumab therapy. Baseline characteristics
were similar between treatment arms (Table A3). OS
outcomes appeared more favourable for patients treated
with panitumumab versus cetuximab (median, 11.3
months versus 9.8 months; HR Z 0.75; 95%
CIZ 0.58e0.97; Figs. 2B and 3A). After adjustment for
baseline covariates including ECOG performance sta-
tus, number of metastatic sites and baseline LDH, the
OS HR was 0.65 (95% CI Z 0.49e0.85) with pan-
itumumab versus cetuximab. Post-progression anti-
tumour therapy was similar between patients previously
treated with bevacizumab who received panitumumab
(47%) and cetuximab (52%). Median PFS was 4.7
months in the panitumumab arm versus 3.2 months in
the cetuximab arm (HR Z 0.85; 95% CI Z 0.66e1.08;
Figs. 2D and 3B).
For patients who had not previously received bev-
acizumab (panitumumab, n Z 373; cetuximab,
n Z 368), median OS (10.0 months versus 9.9 months;
HRZ 1.04, 95% CIZ 0.89e1.21) and PFS (3.8 months
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Fig. 2. Overall survival by treatment arm (A) and for subgroup analysis (B). Progression-free survival by treatment arm (C) and for subset
analysis (D).
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were similar (Fig. A1A, A1B).3.5. Outcomes by skin toxicity severity
In total, 496 patients in the panitumumab arm and 503
patients in the cetuximab arm were included in the skin
toxicity analysis. Baseline demographics and clinical
characteristics were generally similar between patients
with worst-grade 2e4 and worst-grade 1 skin toxicity
(Table A4). Median (range) time to first (any grade) skin
toxicity was 10 (1e213) days with panitumumab treat-
ment and 11 (1e367) days with cetuximab treatment.
Median time to resolution after the last dose of pan-
itumumab or cetuximab was 37 days and 36 days,
respectively.
Patients in the panitumumab arm with worst-grade
2e4 skin toxicity versus those with worst-grade 1 skin
toxicity had longer median OS (14.0 versus 7.0 months;
HR Z 0.47; 95% CI Z 0.39e0.57; Fig. 4A) and PFS
(5.1 versus 2.9 months; Fig. A2A). Median duration of
panitumumab treatment was 22 weeks for patients with
worst-grade 2e4 skin toxicity and 8 weeks for patients
with worst-grade 1 skin toxicity. Similarly, patients in
the cetuximab arm with worst-grade 2e4 skin toxicity
versus those with worst-grade 1 skin toxicity also had
longer median OS (12.6 versus 7.9 months; HR Z 0.57;
95% CI Z 0.47e0.69; Fig. 4B) and PFS (4.9 versus 3.0
months; Fig. A2B). Median duration of cetuximab
treatment was 22 weeks for patients with worst-grade2e4 skin toxicity and 13 weeks for patients with
worst-grade 1 skin toxicity.3.6. Outcomes by hypomagnesaemia development
Overall, 496 patients in the panitumumab arm and 503
patients in the cetuximab arm with prior oxaliplatin and
irinotecan exposure were included in the hypo-
magnesaemia analysis. Baseline demographics and
clinical characteristics were generally similar between
patients with hypomagnesaemia versus patients without
hypomagnesaemia in both treatment arms (Table A5).
Median (range) time to first hypomagnesaemia onset
(any grade) was 83 (1e1130) days with panitumumab
treatment and 57 (1e452) days with cetuximab
treatment.
In the panitumumab arm, similar median OS times
were observed in patients with hypomagnesaemia at
week 5 versus those without (12.0 versus 11.3 months;
HR Z 1.20; 95% CI Z 0.83e1.73; Fig. A3A), and in
patients with 20% decrease in magnesium levels at
week 5 versus those with <20% decrease (10.8 versus
11.3 months; HR Z 1.18; 95% CI Z 0.87e1.61;
Fig. A3B). Patients in the cetuximab arm with hypo-
magnesaemia at week 5 had worse median OS (8.1
versus 10.5 months; HR Z 1.67; 95% CI Z 1.08e2.56;
Fig. A4A) versus those without hypomagnesaemia.
Additionally, patients with 20% decrease in magne-
sium levels from baseline at week 5 versus those with
<20% decrease also had worse median OS (7.3 versus
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Fig. 3. KaplaneMeier curves for overall survival (A) and
progression-free survival (B) for patients with prior bevacizumab
treatment.
Table 2
Adverse events of interest occurring in 10% of patients.
AEs, n (%) Panitumumab
(n Z 496)
Cetuximab (n Z 503)
Any grade Grade 3/4 Any grade Grade 3/4
Rash 249 (50.2) 25 (5.0) 257 (51.1) 18 (3.6)
Dermatitis acneiform 140 (28.2) 17 (3.4) 136 (27.0) 14 (2.8)
Hypomagnesaemia 137 (27.6) 35 (7.0) 91 (18.1) 14 (2.8)
Diarrhoea 92 (18.5) 10 (2.0) 89 (17.7) 9 (1.8)
Dry skin 83 (16.7) 1 (0.2) 79 (15.7) 0 (0)
Pruritus 83 (16.7) 4 (0.8) 89 (17.7) 1 (0.2)
Fatigue 75 (15.1) 14 (2.8) 89 (17.7) 18 (3.6)
Decreased appetite 70 (14.1) 3 (0.6) 78 (15.5) 7 (1.4)
Nausea 68 (13.7) 4 (0.8) 58 (11.5) 7 (1.4)
Abdominal pain 63 (12.7) 19 (3.8) 83 (16.5) 14 (2.8)
Vomiting 59 (11.9) 9 (1.8) 52 (10.3) 7 (1.4)
Paronychia 58 (11.7) 11 (2.2) 75 (14.9) 9 (1.8)
Acne 52 (10.5) 3 (0.6) 69 (13.7) 5 (1.0)
Constipation 41 (8.3) 1 (0.2) 74 (14.7) 3 (0.6)
Pyrexia 31 (6.3) 2 (0.4) 59 (11.7) 4 (0.8)
Other AEs, n (%)
Skin toxicitya 431 (86.9) 63 (12.7) 440 (87.5) 48 (9.5)
Infusion reactions 14 (2.8) 1 (0.2) 63 (12.5) 9 (1.8)
AEs Z adverse events; MedDRA Z Medical Dictionary for Regula-
tory Activities.
a Skin toxicity included multiple terms from the skin and subcu-
taneous tissue disorders system organ class per MedDRA v15.0.
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Fig. 4. KaplaneMeier curves for overall survival by worst skin
toxicity for patients treated with panitumumab (A) and cetuximab
(B). ST = skin toxicity.
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Fig. A4B).
In the panitumumab arm, patients with hypo-
magnesaemia at any point during the study had longer
median OS versus those without hypomagnesaemia
(13.6 versus 8.7 months; HR Z 0.63; 95%
CI Z 0.51e0.78; Fig. 5A). Median duration of treat-
ment was 28 weeks in patients with hypomagnesaemiaand 11 weeks in patients without hypomagnesaemia in
the panitumumab arm. In the cetuximab arm, patients
with hypomagnesaemia at any point during the study
also had longer median OS versus those without hypo-
magnesaemia (12.6 versus 9.3 months; HRZ 0.71; 95%
CI Z 0.56e0.90; Fig. 5B). PFS was also longer in pa-
tients with hypomagnesaemia in both treatment arms
(Fig. A5A, A5B). Median duration of treatment was 27
weeks in patients with hypomagnesaemia and 14 weeks
in patients without hypomagnesaemia in the cetuximab
arm.
In the panitumumab arm, patients with worst-grade
2e4 hypomagnesaemia had a similar median OS to
those with worst-grade 1 hypomagnesaemia (13.6 versus
13.9 months; HR Z 1.12; 95% CI Z 0.78e1.60). In the
cetuximab arm, patients with worst-grade 2e4 hypo-
magnesaemia had a shorter median OS versus those
with worst-grade 1 hypomagnesaemia (10.3 versus 12.6
months; HR Z 1.31; 95% CI Z 0.83e2.05).4. Discussion
In the previously published primary analysis, ASPECCT
met its primary end-point of non-inferiority for OS. In
this final analysis, panitumumab remained non-inferior
to cetuximab for OS: panitumumab retained 111% (95%
CI Z 88%e133%) of the OS benefit of cetuximab over
BSC in patients with chemotherapy-refractory wild-type
KRAS exon 2 mCRC. PFS and ORR remained similar
between arms.
The reported safety profiles for the panitumumab and
cetuximab treatment arms were consistent with those
Fig. 5. KaplaneMeier curves for overall survival by presence or
absence of hypomagnesaemia for patients treated with pan-
itumumab (A) and cetuximab (B).
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signals were identified in either arm. The rates of grade
3 on-target AEs of interest were similar between the
panitumumab and cetuximab treatment arms for skin
toxicity (13%, 10%) and slightly higher with pan-
itumumab for hypomagnesaemia (7%, 3%). The overall
rate of infusion reactions was lower in the panitumumab
arm (2.8%, 12.5%), with grade 3 reactions occurring in
one patient treated with panitumumab and nine patients
treated with cetuximab.
Patients with hypomagnesaemia at any point during
ASPECCT had longer median OS versus those without
hypomagnesaemia for both panitumumab and cetux-
imab arms, consistent with a previous analysis [16].
However, in a landmark analysis at week 5, median OS
in the panitumumab arm for patients with hypo-
magnesaemia was similar to those without (12.0 versus
11.3 months; HR Z 1.20) and for patients with 20%
reduction in magnesium levels from baseline versus
those with <20% reduction (10.8 versus 11.3 months;
HRZ 1.18). In the cetuximab arm, median OS time was
shorter for those with hypomagnesaemia than for those
without (8.1 versus 10.5 months; HR Z 1.67), and for
patients with 20% reduction in magnesium at week 5
versus <20% reduction (7.3 versus 10.8 months;
HRZ 2.16). The cetuximab results were consistent with
results from a 28-day analysis reported from the cetux-
imab monotherapy CO.17 trial [17], but in contrast to
those reported in retrospective analyses of patients
treated with cetuximab in combination with either iri-
notecan [18] or oxaliplatin [19].
It is unclear why patients treated with cetuximab who
developed hypomagnesaemia early may have differentoutcomes compared with patients treated with pan-
itumumab, and why differences exist between studies.
Although no clear biologic explanation has been iden-
tified, based on analyses from previous studies it has
been hypothesised that the predictive value of hypo-
magnesaemia varies for different lines of treatment
(perhaps as a consequence of combination with
chemotherapy) [19,20]. In Vincenzi et al. (2011) and
Stintzing et al. (2013), patients were treated with
cetuximab and irinotecan and cetuximab and oxalipla-
tin, respectively, whereas in ASPECCT and the CO.17
trial, patients were heavily pretreated and received
cetuximab as a monotherapy; the latter two analyses
also excluded patients who had died within 5 weeks (this
analysis) or 28 days (Vickers et al., 2013) of random-
isation. These patients may not have had sufficient time
on therapy to develop hypomagnesaemia and their in-
clusion in the analysis by Vincenzi et al. (2011) may have
confounded the results. Interaction with varying
chemotherapy agents may have also confounded the
results.
For patients who received panitumumab, median OS
appeared moderately longer for those who had previ-
ously received bevacizumab (11.3 months) than for
those who had not (10.0 months). It is possible that
these differences may be the result of an association
between the EGFR and vascular endothelial growth
factor (VEGF) pathways; a recent study has provided
clinical evidence supporting the existence of an interre-
lationship between the VEGF and EGFR signalling
pathways [21]. It is difficult to draw definitive conclu-
sions from ASPECCT as both arms received anti-
EGFR treatment. There is an ongoing debate about
the effect of prior bevacizumab exposure on patient
response to anti-EGFR therapy, with varying outcomes
demonstrated in different analyses [22,23]. One notable
finding from this study was that median OS among
patients who had previously received bevacizumab was
longer for patients who received panitumumab versus
those who received cetuximab (HR Z 0.75; 95%
CI Z 0.58e0.97). Although multivariate analysis of
baseline covariates was conducted (HR Z 0.65; 95%
CI Z 0.49e0.85), this subgroup analysis was not
adjusted for multiplicity, and the possibility that this
finding is an artefact cannot be excluded. Presently, it is
unclear what biologic mechanism might underlie such a
difference in outcomes with panitumumab and cetux-
imab among patients who had previously received
bevacizumab.
Subset analysis of outcomes by skin toxicity severity
indicated that improvements in OS and PFS are asso-
ciated with a higher grade of severity for patients treated
with either panitumumab or cetuximab, consistent with
previous studies [24e26]. However, patients with higher-
grade skin toxicity had longer median duration of
treatment than those with lower-grade skin toxicity.
Because of this difference, it is difficult to determine
T. Price et al. / European Journal of Cancer 68 (2016) 51e5958whether response improvement was linked to higher-
grade skin toxicity or increased treatment exposure.
Regardless of this, the proper management of skin
toxicity remains important to minimise patient
discomfort.
The final analysis results demonstrate that pan-
itumumab is non-inferior to cetuximab and provides a
similar OS benefit to patients with chemotherapy-
refractory wild-type KRAS exon 2 mCRC. The
observed safety profiles between treatment arms were
consistent with previous studies; no new toxicities were
identified. Dosing schedule and the observed incidence
of infusion reactions may be considered when selecting
an anti-EGFR therapy.Funding
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